Weight Training With VR in Out-Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Effects of Weight Training With VR on Pulmonary Function, Exercise Capacity and Quality of Life in Out-Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Using weight training with virtual reality can help after discharge patients of acute exacerbation of chronic obstructive pulmonary disease, which maintained their quality of life, and improved their exercise capacity, pulmonary function, readmission condition.

Study Overview

• Status: Completed
• Conditions: Quality of Life; Pulmonary Rehabilitation; COPD; COPD Exacerbation; Virtual Reality; Pulmonary Function; Muscle Strength; Readmission; Weight Training
• Intervention / Treatment: Other: Education; Other: Supervision upper limb weight training exercise with VR

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a type obstructive lung disease which had become the third leading cause of deaths worldwide. The main symptoms including dyspnea, coughing, sputum production and acute exacerbation of COPD (AECOPD). The physical activity level, muscle power, exercise tolerance and quality of life (QoL) would decline rapidly when an episode of AECOPD occurred, with the worsen of the pulmonary function and activities level, the patient would get weaker and mortality rate would increase. Pulmonary rehabilitation (PR) had become a common-used clinical programs which including (but not limit to) medication, education, psychological support, nutrition consultation and exercise interventions.

In PR programs, exercise had been specifically pointed out for its improvement of physical activity level and quality of life, however, the adherence rate of programs remains low due to lack of motivation and insufficient training effect. Previous interventions preferred aerobic exercise conducting in sitting position considering the long-term sedentary life style of patients. However, such an intervention demonstrated little effect on increasing muscle power of lower extremities, results in insufficient physical activity level and functional performance. Besides, the interventions are usually single and repeatedly limb movement exercise which fail to brings up interests and results in poor motivation of the patients. Literatures review has suggested the highly involvement of upper extremities which is strongly contributed to independently daily living. The implantation of virtual reality in PR program has gained attentions with its advantage of facilitate the motivation. Therefore, the study aims to conduct the muscle strength training including both upper and lower extremities with the combination of virtual reality (VR). Anticipated result expects to provide a research evidence of innovative pulmonary rehabilitation exercise intervention.

The study will recruited 30 participants who will be randomly divided into control and intervention group. Control group will receive routine pulmonary rehabilitation including medication and education, the research stuff will give a brief explanation of home exercise, and weekly telemedicine to follow the exercise intensity and provide conciliation. Intervention group will receive the routine medical care. Extra weight training program targeting on upper extremities with the VR headsets will be conducted with the accompany of the research stuff. 3 times a week for 8 weeks (as a 24-times interference totally) interventions with muscle strength, exercise capacity, pulmonary function and improvement of quality of life will be assess to investigate the training effects. Expected result including the progression of muscle strength, oxygen uptake level, as well as pulmonary performance. The implantation of VR will also improve the motivation to participant, which will further alleviate the symptoms and quality of life. It can also provide some research evidence for clinical therapist to conduct an individualized exercise prescription for COPD.

• Study Type: Interventional
• Enrollment (Actual): 22
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Taiwan
  • Tainan, Taiwan, 704
    • National Cheng Kung University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• hospitalization due to acute exacerbation of chronic obstructive pulmonary disease in preceding 1-year history
• age was between 40 to 85 years old

Exclusion Criteria:

• having a pulmonary rehabilitation in the past 1 month
• comorbidities that don't suitable for pulmonary rehabilitation, such as, untreatable cardiovascular disease, sinus tachycardia (HR>120), hypertension at rest if not adequately controlled, resting systolic blood pressure < 90 mmHg, and exercise contraindication
• advanced cancer with fatigue syndrome
• can't follow the orders
• physical impairment
• psychological impairment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Sham Comparator: Control group; usually care with extra health education on upper limb exercise	Other: Education; Usual pulmonary rehabilitation education and pharmacological therapies, and taught them some limbs exercise, using social application to contact and suggestion giving as supervision.
Experimental: Exercise group; usually care with extra supervision upper limb exercise with VR	Other: Education; Usual pulmonary rehabilitation education and pharmacological therapies, and taught them some limbs exercise, using social application to contact and suggestion giving as supervision.; Other: Supervision upper limb weight training exercise with VR; Participant is supervised by physical therapist to conduct upper limb weight training exercise with VR.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Muscle Strength	using handhold dynamometer to test 5 motions for bilateral side for 3 times.	baseline
Muscle Strength	using handhold dynamometer to test 5 motions for bilateral side for 3 times.	4 weeks
Muscle Strength	using handhold dynamometer to test 5 motions for bilateral side for 3 times.	8 weeks
Muscle Strength	using handhold dynamometer to test 5 motions for bilateral side for 3 times.	12 weeks
Cardiopulmonary exercise function test	using CPET to test for the maximal exercise performance of participant	baseline
Cardiopulmonary exercise function test	using CPET to test for the maximal exercise performance of participant	4 weeks
Cardiopulmonary exercise function test	using CPET to test for the maximal exercise performance of participant	8 weeks
Cardiopulmonary exercise function test	using CPET to test for the maximal exercise performance of participant	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulmonary function test	using spirometry to test for pulmonary function of participant FEV1/FVC in liter	4 times (baseline, 4 weeks, 8 weeks, 12 weeks)
Respiratory muscle force	using digital pressure Guage to test for inspiratory/expiratory muscle force of participant MIP/MEP in cmH2O	4 times (baseline, 4 weeks, 8 weeks, 12 weeks)
Quality of life questionnaire	using questionnaires of EuroQol-5 Dimension (EQ-5D) to test for the quality of life of participant EuroQol-5 Dimension (EQ-5D): 5 levels of health status description to measure quality of life, a higher level means a worsen outcome	4 times (baseline, 4 weeks, 8 weeks, 12 weeks)
Quality of life questionnaire	using modified Medical Research Council dyspnea scale (mMRC) questionnaire to test for the chronic obstructive pulmonary disease symptom of participants Modified Medical Research Council dyspnea scale (mMRC): score from 0-4 to measure the symptom severity of chronic obstructive pulmonary disease, a higher score means a worsen outcome;	4 times (baseline, 4 weeks, 8 weeks, 12 weeks)
Quality of life questionnaire	using chronic obstructive pulmonary disease assessment Test (CAT) questionnaire to test for the chronic obstructive pulmonary disease symptom of participants chronic obstructive pulmonary disease assessment Test (CAT): score from 0-40 to measure the symptom severity of chronic obstructive pulmonary disease, a higher score means a worsen outcome;	4 times (baseline, 4 weeks, 8 weeks, 12 weeks)
Quality of life questionnaire	using clinical chronic obstructive pulmonary disease questionnaire (CCQ) to test for the chronic obstructive pulmonary disease symptom of participants Clinical chronic obstructive pulmonary disease questionnaire (CCQ): score from 0-60 to measure the symptom severity of chronic obstructive pulmonary disease, a higher score means a worsen outcome;	4 times (baseline, 4 weeks, 8 weeks, 12 weeks)

Collaborators and Investigators

• Sponsor: National Cheng-Kung University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 18, 2019
• Primary Completion (Actual): January 17, 2021
• Study Completion (Actual): August 31, 2021

Study Registration Dates

• First Submitted: April 14, 2021
• First Submitted That Met QC Criteria: May 6, 2021
• First Posted (Actual): May 10, 2021

Study Record Updates

• Last Update Posted (Actual): June 10, 2022
• Last Update Submitted That Met QC Criteria: June 9, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Keywords: exercise capacity; virtual reality; functional capacity; Acute exacerbation of chronic obstructive pulmonary disease; upper extremity weight training; adherence rate of exercise
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Body Weight
• Other Study ID Numbers: B-BR-108-038

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No